Web-Based Monitoring Resulted in Longer Overall Survival for Patients in Lung Cancer

Share this content:
Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.
Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer given web-mediated follow-up.
The following article features coverage from the American Society of Clinical Oncology (ASCO) 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Two-year follow-up data from a previous interim analysis dives deeper into the benefit of web-mediated follow-up based on patient-reported outcomes compared with routine surveillance in patients with lung cancer and was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, on Friday,  June 1.1

Previous findings showed a 7 month median overall survival benefit (P = .002) for patients with lung cancer who were given web-based monitoring to detect recurrence after initial treatment compared with scheduled imaging. The researchers theorized that this benefit in overall survival was linked to earlier detection of symptoms and relapses.

Between June 2014 and January 2016, 121 patients were enrolled in the intent-to-test survival analysis. Upon completion of the interim analysis, 10 of the 34 living patients in the control arm were eligible to cross over to the experimental arm of the study. After 2 years of follow-up and 70 deaths observed, the median overall survival was 23 months in the experimental arm and 14.8 months in the control arm without adjustment for crossover (HR 0.62, 95% CI 0.39-0.995, P = .048). Censoring crossover resulted in a hazard ratio of 0.53 (95% CI 0.33-0.85, P = .009).

After the longer follow-up  and  despite  the crossover of  eligible patients, the overall survival findings remained longer for patients with were given web-mediated  follow-up based on patient-reported outcomes compared  with routine follow-up via CT scan.

“This is the first study to show the benefits of PROs during surveillance in cancer patients,” the authors concluded.

Read more of Cancer Therapy Advisor's coverage of the American Society of Clinical Oncology (ASCO) 2018 meeting by visiting the conference page.

Reference

  1. Denis F, Basch EM, Lehtrosne C, et al.  Randomized trial comparing a web-mediated follow-up via patient-reported outcomes (PRO) vs. routine surveillance in lung cancer patients: Final results. J Clin Oncol. 2018: 36, (suppl; abstr 6500). Presented at 2018 ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs